Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

About this update from Phathom Pharmaceuticals, Inc.

[{"type":"image","alt":"Phathom Pharmaceuticals","displaySize":"","headline":null,"caption":"Phathom Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e3Kafcw9GRLzQ8TwZztcdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693","width":300,"height":87}},"lazy":false},{"type":"text","content":"FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results","length":399,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For the three months ended December 31, 2025, Phathom expects to report:","length":72,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenues of approximately $57 million to $58 million","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP operating expenses of approximately $59 million to $61 million","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP operating expenses of approximately $51 million to $53 million, which excludes approximately $8 million of stock-based compensation","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter 2025 net cash usage of approximately $6 million","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of approximately $130 million as of December 31, 2025","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":404,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":476,"olType":false},{"type":"text","content":"Preliminary Full Year 2025 Financial Results","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For the full year 2025, Phathom expects to report:","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenues of approximately $174.5 million to $175.5 million","len...

More updates from Phathom Pharmaceuticals, Inc.